Handelsbanken Fonder AB Acquires 1,352 Shares of argenex SE $ARGX

Handelsbanken Fonder AB boosted its holdings in argenex SE (NASDAQ:ARGX) by 3.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,105 shares of the company’s stock after buying an additional 1,352 shares during the period. Handelsbanken Fonder AB owned approximately 0.07% of argenex worth $30,317,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC grew its position in shares of argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares in the last quarter. Focus Partners Wealth boosted its stake in argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares during the period. Geneos Wealth Management Inc. grew its holdings in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of argenex by 27.1% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,934 shares of the company’s stock valued at $1,066,000 after buying an additional 412 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Trading Down 0.6%

Shares of NASDAQ:ARGX opened at $766.92 on Friday. The company has a 50-day moving average price of $826.36 and a 200-day moving average price of $810.76. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The company has a market cap of $47.46 billion, a price-to-earnings ratio of 39.29, a price-to-earnings-growth ratio of 0.67 and a beta of 0.37.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 63.59%. The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. As a group, research analysts forecast that argenex SE will post 3.13 EPS for the current fiscal year.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ARGX shares. Wolfe Research restated a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. JPMorgan Chase & Co. increased their target price on shares of argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Robert W. Baird raised their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Finally, Evercore upped their price objective on shares of argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and an average target price of $999.22.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.